Oligo expansion for CatSci
CatSci has made a “significant” investment to support the development of oligonucleotide capability at its site in Cardiff, UK. This follows recent investment in the firm by Keensight Capital to support its strategic growth plans.
The company will now be able to manufacture oligonucleotides from nanomole quantities up to 30 grams using solid phase synthesis, as well as to carry out research into new manufacturing approaches aligned with its green chemistry commitments. It will all be led by Dr Nigel Richardson (pictured), director of new modalities, who previously led GSK’s oligonucleotide therapy for Duchenne muscular dystrophy into the final stages of development and regulatory submission.